The content on this site is intended for healthcare professionals only
Dr Bussel discusses the prolonged responses to TPO-R agonists at a symposium on idiopathic thrombocytopenic purpura at EHA 2014.
GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the Chairs & speakers and provided input into the symposium agenda/content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
The current status of multiple myeloma diagnosis and treatment
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG
